At AVM Biotechnology, we are dedicated to halting progression of the disease and improving daily quality of life and function.
Clinical use of stem cells as regenerative therapy for musculoskeletal conditions and specifically, as a treatment for knee OA, has recently grown in popularity and is supported by evidence from clinical studies (Cui 2016; Kristjannsen 2014; Shapiro 2017; Veronesi 2013; Wong 2013). Stem cell therapy has provided benefits for OA, but the benefits have not been complete nor permanent.
A single oral dose of AVM0703 can dramatically enhance and maintain the benefits of stem cell treatment AVM0703 has issued and pending worldwide patents to provide exclusivity as well as freedom to operate.
AVM0703 pre-treatment will make your stem cell product the most effective and sought after on the market. We are seeking stem cell or device partners to develop and commercialize our lead product AVM0703 worldwide for musculoskeletal and other diseases.
OA is a progressive degenerative disease that causes increasing pain, impairment and disability. Half of the world’s population aged 65 years or older has OA. Statistically, it is the most prevalent disorder of articulating joints in humans.
In OA of the knee, the cartilage in the knee joint gradually wears away and becomes frayed and rough, and the buffering space between the bones decreases. This can lead to bone rubbing on bone and produce painful bone spurs. Symptoms include stiffness, pain, inflammation, and creaking noises in the joint.
Currently available treatments for knee OA
While the available treatments seek to alleviate pain or improve mobility, these treatments rarely stop the progression of the disease or regenerate damaged cartilage. For knee OA, the American College of Rheumatology (ACR) and American Academy of Orthopedic Surgeons (AAOS) guidelines recommend using Oral NSAIDs, Topical NSAIDs, and Tramadol which unfortunately have undesirable side effects.
|EQ-101||Mare/NA||Old mare with OA in multiple joints; pilot study case||6mg/kg of AVM0703 (IV)||Well tolerated; no side effects noted||No infections, no laminitis, no Cushing’s syndrome|
|EQ-102||Young mare race horse with OA in one joint; pilot study case||No infections, no laminitis, liver enzymes tested normal|
|EQ-104||Mare/8||Normal mare without OA||High dose well tolerated|
|EQ-109||Mare/NA||Normal mares without OA; Stem cell (SC) biodistribution study||Labeled allogeneic adipose MSC (IA)||Peak number of synovial MSC detected at 15 min. Elimination of synoval MSC evident by 4-8 hours|
|EQ-110||Labeled allogeneic adipose MSC (IA)|
|EQ-103||Mare/NA||Normal mare with OA||3mg/kg of AVM0703(IV); allogeneic adipose mesenchymal SC (IA)||Well tolerated; no side effects noted||Improvement in treated joints|
|EQ-105||Gelding/35||OA; advanced degenerated joint disease in the pasterns, hocks and knees||6mg/kg of AVM0703(IV); allogeneic adipose mesenchymal SC (IA)||Less pain in flexion of carpi; lameness in fore/hindlimbs improved by 1 whole grade|
|EQ-106||Mare/6||Normal mare without OA||3mg/kg of AVM0703(IV); allogeneic adipose mesenchymal SC (IA)||Improvement in treated joints; back to dressage training* in 4 months|
|EQ-107||Gelding/8||Improvement in treated joints|
|EQ-108||Gelding/14||Tendon injury (DDFT) grade 3||Remarkable improvement observed at 3 weeks, back to light work* in 6 months instead of 12|
|EQ-111||Mare/15 months||OA; congenital OCD 3 lesions, right hock, 3 prior surgeries (partial response)||Expanded autologous bone marrow MSC (Intra-articular injection)||Lameness eliminated in 2 weeks|